Apriem Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Apriem Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-100	Closed	-$4K	–	627
2016 Q2	$4K	Hold	100	–	–	﹤0.01%	494
2016 Q1	$4K	Hold	100	–	–	﹤0.01%	467
2015 Q4	$5K	Hold	100	–	–	﹤0.01%	437
2015 Q3	$5K	Hold	100	–	–	﹤0.01%	412
2015 Q2	$6K	Hold	100	–	–	﹤0.01%	466
2015 Q1	$6K	Hold	100	–	–	﹤0.01%	461
2014 Q4	$5K	Hold	100	–	–	﹤0.01%	433
2014 Q3	$5K	Hold	100	–	–	﹤0.01%	441
2014 Q2	$4K	Hold	100	–	–	﹤0.01%	406
2014 Q1	$4K	Hold	100	–	–	﹤0.01%	424
2013 Q4	$4K	Hold	100	–	–	﹤0.01%	430
2013 Q3	$4K	Hold	100	–	–	﹤0.01%	428
2013 Q2	$3K	Buy	+100	New	+$2.84K	﹤0.01%	413

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SAM

SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Apriem Advisors's PBE Position: Q3 2016 in Review

Apriem Advisors sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2016, closing a stake of 100 shares — an estimated $4K sold.

Apriem Advisors first reported a position in PBE in Q2 2013 and held it in 13 quarters. The position peaked at $6K in Q2 2015. 68 funds tracked by Wall St. Rank hold PBE as of Q3 2016.

Apriem Advisors reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2016 after selling out during the quarter.
Apriem Advisors sold 100 Invesco Biotechnology & Genome ETF shares in Q3 2016, an estimated $4K.
Apriem Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and held it in 13 quarters.
Apriem Advisors's Invesco Biotechnology & Genome ETF position peaked at $6K in Q2 2015.
68 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2016.

Based on Apriem Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.